Phase II trial to evaluate SGN CD19A along with R-ICE chemotherapy in patients with diffuse large B-cell lymphoma

Trial Profile

Phase II trial to evaluate SGN CD19A along with R-ICE chemotherapy in patients with diffuse large B-cell lymphoma

Planning
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2015

At a glance

  • Drugs Denintuzumab mafodotin (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
  • Indications B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 10 Feb 2015 Seattle Genetics plans to initiate this study in 2015.
    • 27 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top